A leading inhalation expert
Iconovo develops inhaled medicines in partnership with pharma companies, combining patented dry powder inhalers and formulation expertise for end-to-end development. Expanding beyond respiratory care, we focus on areas where inhalation offers patient-friendly, precise and fast systemic delivery — including inhaled semaglutide in our pipeline as an alternative to injections for biologics losing exclusivity.
What we do
Iconovo is a fully integrated inhalation partner, supporting projects from molecule to market. We can manage the entire journey from concept to finished pharmaceutical product, or collaborate with partners who lead late-stage development and manufacturing. Our strength lies in combining deep inhaler expertise with advanced dry powder formulation, using five proprietary device platforms tailored to specific drug properties.
News & events
Pipeline
Iconovo’s pipeline outlines the development progress of each platform and project, highlighting the path forward in collaboration with our partners.
Partner with us
Partner with Iconovo for patented inhaler platforms, strong formulation expertise, and an efficient path to market that maximizes commercial value.
We accelerate access to innovative inhalation medicines
As the global pharmaceutical industry seeks more effective treatments, Iconovo pushes the boundaries of what is achievable with inhaled therapies. Based in Sweden, Iconovo is a leading expert in developing and commercializing advanced inhalation platforms and medicines.
With a robust IP portfolio and an extensive inhalation-based product pipeline, we are a trusted partner in the industry. Iconovo is listed on Nasdaq First North Growth Market (ICO).